Advertisement

Pharmaceuticals in the Canadian Environment

  • C. Metcalfe
  • X.-S. Miao
  • W. Hua
  • R. Letcher
  • M. Servos

Abstract

One of the first reports of the release of pharmaceutically active compounds (PhACs) into the environment was a study conducted in Canada on the concentrations of selected drugs in the effluent from a Vancouver sewage treatment. Two analgesic/antiinflammatory drugs, ibuprofen and naproxen were identified in the municipal wastewater from Vancouver (Rogers et al. 1986). Since that study, the issue of the release of PhACs into the environment has developed into an area of emerging interest (Halling-Sørensen et al. 1998; Daughton and Ternes 1999; Servos et al. 2001, 2002; Heberer 2002a,b). Most of these drugs or their metabolites are excreted or are discarded into urban wastewaters and eventually make their way to wastewater treatment plants (WWTPs). Within WWTPs, drugs may be rapidly degraded and mineralised, or these substances (or their metabolites) may be relatively persistent. Hydrophilic compounds that are resistant to degradation may remain dissolved in the aqueous phase of the WWTP effluent, or more hydrophobic substance may bind to WWTP biosolids (i.e. “sludge”). Thus, these compounds may enter the environment through the discharge of WWTP effluents into receiving waters, or they may enter the environment in association with biosolids that are deposited in landfills or spread on agricultural land for soil amendment. PhACs bound to biosolids may leach into underlying groundwater, which may be used as a source of potable water (Heberer 2002a,b; Sacher et al. 2001). PhACs applied to agricultural fields may also be transported by runoff into the surrounding surface water. PhACs discharged into surface water have the potential to contaminate sources of drinking water (Heberer et al.1997, 2001).

Keywords

Tiaprofenic Acid Clofibric Acid Acidic Drug Drinking Water Treatment Plant Pipemidic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Buser H-R, Müller MD, Theobald N (1998a) Occurrence of the pharmaceutical drug clofibric acid and the herbicide mecoprop in various Swiss lakes and in the North Sea. Environ Sci Technol 32: 188–192CrossRefGoogle Scholar
  2. Buser HR, Poiger T, Muller MD (1998b) Occurrence and fate of the pharmaceutical drug diclofenac in surface water: rapid photodegradation in a lake. Environ Sci Technol 32: 3449–3456CrossRefGoogle Scholar
  3. Christensen FM (1998) Pharmaceuticals in the environment–a human risk? Regulat Toxicol Pharmacol 28: 212–221CrossRefGoogle Scholar
  4. Christian T, Schneider RJ, Farber HA, Skutlarek D, Meyer M, Goldbach HE (2003) Determination of antibiotic residues in manure, soil, and surface water. Acta Hydroch Hydrob 31: 36–44CrossRefGoogle Scholar
  5. Collier AM, Goldstein GM, Shrewsbury RP, Davis SM, Koch GG, Zhand CA, Benowitz NL, Lewtas J, Williams RW (1994) Continine elimination and its use as a biomarker in young children involuntarily exposed to environmental tobacco smoke. Indoor Environment 3: 353–359CrossRefGoogle Scholar
  6. Daughton CG, Ternes TA (1999) Pharmaceuticals and personal care products in the environment: agents of subtle change? Environ Health Perspect 107: 907–938CrossRefGoogle Scholar
  7. Dorn PB (1996) An industrial perspective on whole effluent toxicity testing. In: Groth DR, Dickson KL, Reed-Judkins LH (eds) Whole effluent toxicity testing: an evaluation of methods and prediction of receiving system impacts. SETAC Press, Pensacola, FL, USA, pp 34–47Google Scholar
  8. Dybing E (2002) Development and implementation of the IPCS conceptual framework for evaluation mode of action of chemical carcinogens. Toxicology 181 /182: 121–125CrossRefGoogle Scholar
  9. Federal Drug Administration (1998) Guidance for industry-environmental assessment of human drugs and biologics applications, Revision 1. FDA, Centre for Drug Evaluation and Research, Rockville, Maryland, USAGoogle Scholar
  10. Fong PP (1998) Zebra mussel spawning is induced in low concentrations of putative serotonin reuptake inhibitors. Biol Bull 194: 143–149CrossRefGoogle Scholar
  11. Halling-Sorensen B, Nielsen SN, Lanzky PF, Ingerslev F, Holten-Lützhoft HC, Jorgensen SC (1998) Occurrence, fate and effects of pharmaceutical substances in the environment–a review. Chemosphere 36: 357–393CrossRefGoogle Scholar
  12. Halling-Sorensen B, Holten-Lützhoft H-C, Andersen HR, Ingerslev F (2000) Environmental risk assessment of antibiotics: comparison of mecillinam, trimethoprim and ciprofloxacin. J Antimicrob Chemoth 46 (Suppl S1): 53–58CrossRefGoogle Scholar
  13. Hartig C, Storm T, Jekel M (1999) Detection and identification of sulfonamide drugs in municipal waste water by liquid chromatography coupled with electrospray ionisation tandem mass spectrometry. J Chromatogr A 854: 163–173CrossRefGoogle Scholar
  14. Heberer Th (2002a) Occurrence, fate and removal of pharmaceutical residues in aquatic environment: a review of recent research data. Toxicol Lett 131: 5–17CrossRefGoogle Scholar
  15. Heberer Th (2002b) Tracking persistent pharmaceutical residues from municipal sewage to drinking water. J Hydrol 266: 175–189CrossRefGoogle Scholar
  16. Heberer Th, Dünnbier U, Reilich Ch, Stan H-J (1997) Detection of drugs and drug metabolites in groundwater samples of a drinking water treatment plant. Fresenius Environ Bull 6: 438–443Google Scholar
  17. Heberer Th, Fuhrman B, Schmidt-Bäumler K, Tsipi D, Koutsouba V, Hiskia A (2001) Occurrence of pharmaceutical residues in sewage, river, ground and drinking water in Greece and Germany. In: Daughton CG, Jones-Lepp T (eds) Pharmaceuticals and personal care products in the environment: scientific and regulatory issues. American Chemical Society, Washington DC (Symposium Series 791: 70–83 )CrossRefGoogle Scholar
  18. Heberer Th, Reddersen K, Mechlinski A (2002) From municipal sewage to drinking water: fate and removal of pharmaceutical residues in the aquatic environment in urban areas. Water Sci Technol 46: 81–88Google Scholar
  19. Hirsch CA, Messenger RJ, Brannon JL (1978) Fenoprofen: drug form selection and preformulation stability studies. J Pharm Sci 67: 231–236CrossRefGoogle Scholar
  20. Hirsch R, Ternes T, Haberer K, Kratz K-L (1999) Occurrence of antibiotics in the aquatic environment. Sci Total Environ 255: 19–118Google Scholar
  21. Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based propective studies. J Cardiovasc Risk 3: 213–219CrossRefGoogle Scholar
  22. Hooper DC, Wolfson JS (eds) (1993) Quinolone antimicrobial agents, 2nd edn. American Society of Microbiology, Washington DCGoogle Scholar
  23. Hua W, Miao X-S, Bennett ER, Metcalfe CD, Letcher RJ (2004a) Neutral and acidic pharmaceuticals and major triazine herbicides in wastewater effluent and surface waters from the upper Detroit River (to be published )Google Scholar
  24. Hua W, Jasim SY, Bennett ER, Mazloum S, Letcher RJ (2004b) The effects of ozone versus conventional treatment processes on neutral and acidic pharmaceuticals and atrazine on Detroit River drinking water for the City of Windsor, Canada (to be published)Google Scholar
  25. Hua W, Bennett ER, Letcher RJ (2004c) Triclosan in wastewater effluent and surface water from the Detroit River by liquid chromatography-electrospray-tandem mass spectrometry. Environ Sci Technol (to be published )Google Scholar
  26. Huber MM, Canonica S, Park G-Y, Gunten UV (2003) Oxidation of pharmaceuticals during ozonation and advanced oxidation processes. Environ Sci Technol 37: 1016–1024CrossRefGoogle Scholar
  27. Johston L, Mackay L, Croft M (2002) Determination of quinolones and fluoroquinolones in fish tissue and seafood by high-performance liquid chromatography with electrospray ionisation tandem mass spectrometric detection. J Chromatogr A 982: 97–109CrossRefGoogle Scholar
  28. Khan SJ, Ongerth JE (2002) Estimation of pharmaceutical residues in primary and secondary sewage sludge based on quantities of use and fugacity modeling. Water Sci Technol 46: 105–113Google Scholar
  29. Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, Buxton HT (2002) Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999–2000: a national reconnaissance. Environ Sci Technol 36: 1202–1211CrossRefGoogle Scholar
  30. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ (2001) Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmaco Ther 69: 340–345CrossRefGoogle Scholar
  31. Leviton A, Cowan L (2002) A review of the literature relating caffeine consumption by women to their risk of reproductive hazards. Food Chem Toxicol 40: 1271–1310CrossRefGoogle Scholar
  32. López-Martinez L, López-de-Alba PL, de-Leon-Rodriguez LM, Yepez-Murrieta ML (2002) Simultaneous determination of binary mixtures of trimethoprim and sulfamethoxazole or sulpha-methoxypyridazine by the bivariate calibration spectrophotometric method. J Pharm Biomed Anal 30: 77–85CrossRefGoogle Scholar
  33. Mazloum S (2002) Improvement and optimization of the A. H. Weeks Plant water treatment processes. MSc thesis, Department of Engineering, University of Windsor, Windsor, ON, CanadaGoogle Scholar
  34. Metcalfe CD, Metcalfe TL, Kiparissis Y, Koenig BD, Khan C, Hughes RJ, Croley TR, March RE, Potter T (2001) The estrogenic potency of chemicals in sewage treatment plant effluents as determined by in vivo assays with the Japanese medaka, Oryzias latipes. Environ Toxicol Chem 20: 297–308Google Scholar
  35. Metcalfe CD, Koenig BG, Bennie DT, Servos M, Ternes TA, Hirsch R (2003a) Occurrence of neutral and acidic drugs in the effluents of Canadian sewage treatment plants. Environ Toxicol Chem 22: 2872–2880CrossRefGoogle Scholar
  36. Metcalfe CD, Miao X-S, Koenig BG, Struger J (2003b) Distribution of acidic and neutral drugs in surface water near sewage treatment plants in the lower Great Lakes, Canada. Environ Toxicol Chem 22: 2881–2889CrossRefGoogle Scholar
  37. Miao X-S, Metcalfe CD (2003a) Pharmaceutical analysis in aqueous samples using positive and negative voltage switching microbore LC-ESI-MS/MS. J Mass Spectrom 38: 27–34CrossRefGoogle Scholar
  38. Miao X-S, Metcalfe CD (2003b) Determination of cholesterol-lowering statin drugs in aqueous samples using liquid chromatography-electrospray ionization tandem mass spectrometry. J Chromatogr A 998: 133–141CrossRefGoogle Scholar
  39. Miao X-S, Metcalfe CD (2003c) Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry. Anal Chem 75: 3731–3738CrossRefGoogle Scholar
  40. Miao X-S, Koenig BG, Metcalfe CD (2002) Analysis of acidic drugs in the effluents of sewage treatment plants using liquid-chromatography-electrospray ionization tandem mass spectrometry. J Chromatog A 952: 139–147CrossRefGoogle Scholar
  41. Miao X-S, March RE, Metcalfe CD (2003) A tandem mass spectrometric study of the N-oxides, quinoline N-oxide, carbadox, and olaquindox, carried out at high mass accuracy using electrospary ionization. Int J Mass Spectrom 230: 123–133CrossRefGoogle Scholar
  42. Miao X-S, Bishay F, Chen M, Metcalfe CD (2004) Occurrence of antimicrobials in the final effluents from wastewater treatment plants in Canada. Environ Sci Technol (to be published )Google Scholar
  43. Nabholtz J-M, Reese D, Lindsay M-A, Riva A (2002) Evidence for the use of chemotherapy in breast cancer. Int J Oncol 7: 254–264CrossRefGoogle Scholar
  44. Oka H, Ito Y, Matsumoto H (2000) Chromatographic analysis of tetracycline antibiotics in foods. J Chromatogr. A 882: 109–133CrossRefGoogle Scholar
  45. Reese RE, Betts RF (1991) Practical approach to infectious diseases, 3rd edn. Little Brown, Boston Renshaw PF, Guimaraes AR, Fava M (1992) Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. Am J Psychiatry 149:1592–1594Google Scholar
  46. Richardson ML, Bowron JM (1985) The fate of pharmaceutical chemicals in the aquatic environment–a review. J Pharm Pharmacol 37: 1–12CrossRefGoogle Scholar
  47. Ring BJ, Eckstein JA, Gillespie JS, Binkley SN, Vandenbranden M, Wrighton SA (2001) Identification of the human cytochromes P450 responsible for in vitro formation of r-and s-norfluoxetine. J Pharmacol Exp Ther 297: 1044–1050Google Scholar
  48. Rogers IH, Birtwell IK, Kruznyski GM (1986) Organic extractables in municipal wastewater of Vancouver, British Columbia. Water Pollut Res J Can 21: 187–204Google Scholar
  49. Sacher F, Lange FT, Brauch H-J, Blankenhorn I (2001) Pharmaceuticals in groundwaters: analytical methods and results of a monitoring program in Baden-Württemberg, Germany. J Chromatogr A 938: 199–210CrossRefGoogle Scholar
  50. Servos MR, Chambers P, Macdonald R, Van Der Kraak G (2001) Municipal wastewater effluents: water quality issues in Canada. In: NWRI (ed) Threats to sources of drinking water and aquatic ecosystem health in Canada (NWRI Scientific Assessment Report Series 1:37–40, ISSN 1499–5905 )Google Scholar
  51. Servos MR, Innes E, Given J, Ostapyk K, Topp E, McInnis R, Starodub ME (2002) Assessment and management of pharmaceuticals and personal care products in the Canadian environment. Proceedings of a Multi-Stakeholder Workshop, 24–27 February 2002, Environment Canada and Health Canada (special publication )Google Scholar
  52. Servos MR, Smith M, McInnis M, Burnison K, Seto P, Smyth SA, Backus S (2004a) Presence and removal of acidic drugs in drinking water treatment plants in Ontario, Canada. Water Qual Res J Can (to be published )Google Scholar
  53. Servos MR, Bennie DT, Burnison BK, Jurkovic A, McInnis R, Neheli T, Schnell A, Seto P, Smyth SA, Ternes TA (2004b) Removal of hormones,17f3-estradiol and estrone, in Canadian municipal wastewater treatment plants. Sci Total Environ (to be published)Google Scholar
  54. Ternes TA (1998) Occurrence of drugs in German sewage treatment plants and rivers. Water Res 12: 3245–3260CrossRefGoogle Scholar
  55. Ternes TA, Kreckel P, Mueller J (1999a) Behavior and occurrence of estrogens in municipal sewage treat- ment plants–II. Aerobic batch experiments with activated sludge. Sci Total Environ 225: 91–101CrossRefGoogle Scholar
  56. Ternes TA, Stumpf M, Mueller I, Haberer K, Wilken R-D, Servos M (1999b) Behaviour and occurrence of estrogens in municipal sewage treatment plants–I. Investigations in Germany, Canada and Brazil. Sci Total Environ 225: 81–90CrossRefGoogle Scholar
  57. Ternes TA, Meisenheimer M, McDowell K, Sacher F, Brauch H-J, Haist-Gulde B, Preuss G, Wilme U, ZuleiSeibert N (2002) Removal of pharmaceuticals during drinking water treatment. Environ Sci Technol 36: 3855–3863CrossRefGoogle Scholar
  58. Vartanian VH, Goolsby B, Brodbelt JS (1998) Identification of tetracycline antibiotics by electrospray ionization in a quadrupole ion trap. J Am Soc Mass Spectrom 9: 1089–1098CrossRefGoogle Scholar
  59. Voogd CE, van der Stel JJ, Jacobs JJJAA (1980) The mutagenic action of quindoxin, carbadox, olaquindox and some other N-oxides on bacteria and yeast. Mutat Res 78: 233–242CrossRefGoogle Scholar
  60. Webb S (2001) A data-based perspective on the environmental risk assessment of human pharmaceuticals III–Indirect human exposure. In: Kämmerer K (ed) Pharmaceuticals in the environment. Sources, fate, effects and risks. Springer-Verlag, Berlin, pp 221–230Google Scholar
  61. Webb S, Ternes T, Gibert M, Olejniczak K (2003) Indirect human exposure to pharmaceuticals via drinking water. Toxicol Lett 142: 157–167CrossRefGoogle Scholar
  62. Zwiener C, Fimmel FH (2001) Oxidative treatment of pharmaceuticals in water. Wat Res 34: 1881–1885Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • C. Metcalfe
  • X.-S. Miao
  • W. Hua
  • R. Letcher
  • M. Servos

There are no affiliations available

Personalised recommendations